Enhancement of NK Cell Antitumor Effector Functions Using a Bispecific Single Domain Antibody Targeting CD16 and the Epidermal Growth Factor Receptor
Elisa C. Toffoli(Amsterdam University Medical Centers), Roeland Lameris(Amsterdam UMC Location Vrije Universiteit Amsterdam), Bruce Walcheck(University of Veterinary Science), Abdolkarim Sheikhi(Dezful University of Medical Sciences), Jurriaan B. Tuynman(Amsterdam Neuroscience), Tanja D. de Gruijl(Dutch Cancer Society), Jan Spanholtz(AIMM Therapeutics (Netherlands)), Lisa A. King(Leiden University Medical Center), Amanda van Vliet, Henk M.W. Verheul(Erasmus MC Cancer Institute)
Cited by 22
Related Papers
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
|New England Journal of Medicine|2012|5.5k
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
|The Lancet Oncology|2015|2.6k
Epidemic Profile of Shiga-Toxin–Producing<i>Escherichia coli</i>O104:H4 Outbreak in Germany
|New England Journal of Medicine|2011|1.1k
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
|Journal of Clinical Oncology|2021|795